MedTrace Logo

Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk

NCT04753372 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 645

Last updated 2023-09-28

No results posted yet for this study

Summary

Registry to describe the impact in terms of effectiveness and safety of the combination treatment of rivaroxaban 2.5 mg twice daily with aspirin on clinical outcomes and practices in a real-life Dutch patient population that are at high risk of ischemic events.

Conditions

  • Coronary Artery Disease (CAD)
  • Peripheral Arterial Disease (PAD)

Interventions

DRUG

Rivaroxaban 2.5 MG [Xarelto]

rivaroxaban 2.5mg bid on top of ASA for CAD and/or PAD

Sponsors & Collaborators

  • Diagram B.V.

    collaborator OTHER

  • Maatschap Cardiologie Zwolle

    lead OTHER

Principal Investigators

  • Rik Hermanides, MD, PhD · Isala

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-21
Primary Completion
2023-09-13
Completion
2023-09-13

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04753372 on ClinicalTrials.gov